| Initial U.S. Approval: 2015
Mechanism of Action: The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.
|INDICATIONS AND USAGE: VRAYLAR™ is indicated for the:
Treatment of schizophrenia.
Acute treatment of manic or mixed episodes associated with bipolar I disorder.
VRAYLAR (cariprazine) capsules are available in four strengths.
1.5 mg capsules: White cap and body imprinted with "FL 1.5"
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.